Patents by Inventor Michael McNevin

Michael McNevin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
    Patent number: 10167298
    Abstract: The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: January 1, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael McNevin, Yong Liu, Ian Mangion, Alfred Lee, Joyce Stellabott, Benjamin D. Sherry, Gary Martin, Kung-I Feng, Scott Schultz, Ryan Cohen, Yanfeng Zhang
  • FIXED-DOSE COMBINATIONS OF ANTIVIRAL COMPOUNDS
    Publication number: 20180228826
    Abstract: The present disclosure is directed to compositions comprising blended materials comprising a substantially crystalline HCV nucleotide polymerase inhibitor; a first solid dispersion formulation, which comprises an HCV NS5a inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients; and a second solid dispersion formulation, which comprises an HCV NS3 inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 16, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: David Harris, James DiNunzio, William A Marinaro, Sutthilug Sotthivirat, Chad David Brown, Sundeep Sudish Dhareshwar, Jesse Lee Kuiper, Yung-Chi Lee, Craig Alfred McKelvey, Michael McNevin, Elise Topol Miller, Li Xiong
  • FIXED-DOSE COMBINATIONS OF ANTIVIRAL COMPOUNDS
    Publication number: 20180228827
    Abstract: The present disclosure is directed to compositions comprising blended materials comprising a substantially crystalline HCV nucleotide polymerase inhibitor; a solid dispersion formulation, which comprises an HCV NS5a inhibitor or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable polymers or a mixture thereof, and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more pharmaceutically acceptable surfactants or a mixture thereof; and optionally one or more excipients.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 16, 2018
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: William A Marinaro, David Harris, James DiNunzio, Sutthilug Sotthivirat, Sundeep Sudish Dhareshwar, Gerard Ross Klinzing, Jesse Lee Kuiper, Yung-Chi Lee, Craig Alfred McKelvey, Michael McNevin, Li Xiong
  • METHODS FOR MAKING PHARMACEUTICAL SOLID DOSAGE FORMS OF SPRAY-DRIED DISPERSIONS
    Publication number: 20180221282
    Abstract: A process for drying a spray dried dispersion, comprising: a) providing a spray-dried dispersion comprising particles wherein the particles comprise an active agent and a polymer and optionally one or more surfactants, the dispersion having an average particle diameter of less than about 100 m; b) blending an amount of silicon dioxide with the dispersion to form a dispersion-silicon dioxide blend, wherein the amount of silicon dioxide relative to the amount of dispersion is between about 0.5 and 2.0% by weight; c) drying the blend with a secondary dryer.
    Type: Application
    Filed: July 29, 2016
    Publication date: August 9, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yung-Chi Lee, David Harris, Justin David Moser, Michael McNevin, Amber Broadbent, Robert Hall, Ari Ericson
  • Pharmaceutical salts of an orexin receptor antagonist
    Patent number: 9969725
    Abstract: The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is further directed to pharmaceutical compositions comprising pharmaceutically acceptable salts of suvorexant.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: May 15, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael McNevin, Sachin Lohani
  • PHARMACEUTICAL SALTS OF AN OREXIN RECEPTOR ANTAGONIST
    Publication number: 20170044149
    Abstract: The invention is directed to pharmaceutically acceptable salts of suvorexant, which is an antagonist of orexin receptors. The pharmaceutically acceptable salts of suvorexant are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is further directed to pharmaceutical compositions comprising pharmaceutically acceptable salts of suvorexant.
    Type: Application
    Filed: April 16, 2015
    Publication date: February 16, 2017
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Michael MCNEVIN, Sachin LOHANI
  • PSEUDOPOLYMORPHS OF AN HCV NS5A INHIBITOR AND USES THEREOF
    Publication number: 20160311834
    Abstract: The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.
    Type: Application
    Filed: October 24, 2014
    Publication date: October 27, 2016
    Inventors: Michael McNEVIN, Yong LIU, Ian MANGION, Alfred LEE, Joyce STELLABOTT, Benjamin D. SHERRY, Gary MARTIN, Kung-I FENG, Scott SHULTZ, Ryan COHEN, Yanfeng ZHANG
  • Crystalline forms of a factor Xa inhibitor
    Patent number: 8946269
    Abstract: Provided herein are crystalline forms of a maleate salt of betrixaban, compositions and methods of preparation or use thereof.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: February 3, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Vincent R. Capodanno, Liam Corcoran, Michael McNevin, Itzia Zoraida Arroyo, Robert M. Wenslow, Richard G. Ball, Eric L. Margelefsky, Timothy K. Maher, Anjali Pandey
  • METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR
    Publication number: 20140323497
    Abstract: This invention is directed to methods of inhibiting coagulation or treating thrombosis using a factor Xa inhibitor and a P-glycoprotein (Pgp) inhibitor. The invention is also directed to formulations used in the methods.
    Type: Application
    Filed: November 12, 2013
    Publication date: October 30, 2014
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Uma Sinha, George A. Mansoor, Anne Hermanowski Vosatka, Vincent R. Capodanno, Robert M. Wenslow, Richard G. Ball, Eric L. Margeiefsky, Timothy K. Maher, Itzia Zoraida Arroyo, Brett Lauring, Liam Corcoran, William Denney, Michael McNevin, Anjali Pandey
  • METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR
    Publication number: 20120095019
    Abstract: This invention is directed to methods of inhibiting coagulation or treating thrombosis using a factor Xa inhibitor and a P-glycoprotein (Pgp) inhibitor. The invention is also directed to formulations used in the methods.
    Type: Application
    Filed: August 31, 2011
    Publication date: April 19, 2012
    Inventors: Uma Sinha, George A. Mansoor, Anne Hermanowski Vosatka, Vincent R. Capodanno, Robert M. Wenslow, Richard G. Ball, Eric L. Margelefsky, Timothy K. Maher, Itzia Zoraida Arroyo, Brett Lauring, Liam Corcoran, William Denney, Michael McNevin, Anjali Pandey
  • CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR
    Publication number: 20120071519
    Abstract: Provided herein are crystalline forms of a maleate salt of betrixaban, compositions and methods of preparation or use thereof.
    Type: Application
    Filed: August 31, 2011
    Publication date: March 22, 2012
    Inventors: Vincent R. Capodanno, Liam Corcoran, Michael McNevin, Itzia Zoraida Arroyo, Robert M. Wenslow, Richard G. Ball, Eric L. Margelefsky, Timothy K. Maher, Anjali Pandey